Harrison, S. A., Abdelmalek, M. F., Neff, G. W., Gunn, N., Guy, C. D., Alkhouri, N., … Lieu, H. (2021). TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS. In HEPATOLOGY (Vol. 74, pp. 5A-6A).

Harrison, Stephen A., Manal F. Abdelmalek, Guy W. Neff, Nadege Gunn, Cynthia D. Guy, Naim Alkhouri, Mustafa Bashir, et al. “TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS.” In HEPATOLOGY, 74:5A-6A, 2021.

Harrison SA, Abdelmalek MF, Neff GW, Gunn N, Guy CD, Alkhouri N, et al. TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS. In: HEPATOLOGY. 2021. p. 5A-6A.

Harrison, Stephen A., et al. “TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS.” HEPATOLOGY, vol. 74, 2021, pp. 5A-6A.

Harrison SA, Abdelmalek MF, Neff GW, Gunn N, Guy CD, Alkhouri N, Bashir M, Freilich B, Almeda J, Knapple W, Kohli A, Khazanchi A, Sheikh MY, Leibowitz M, Hogan R, White J, Kayali Z, Rinella ME, Siddiqui MS, Kipnes M, Moussa SE, Ortiz-Lasanta G, Poulos J, Younes Z, Bansal MB, Baum SJ, Borg B, Ruane PJ, White A, Merkes K, Rashmee P, Thuluvath PJ, Gottwald M, Khan M, Chen C, Yan AZ, Melchor-Khan L, Chang W, DePaoli A, Ling L, Lieu H. TOPLINE RESULTS FROM THE ALPINE 2/3 STUDY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PHASE 2b TRIAL EVALUATING 3 DOSES OF THE FGF19 ANALOGUE ALDAFERMIN ON LIVER HISTOLOGY IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS AND STAGE 2 OR 3 FIBROSIS. HEPATOLOGY. 2021. p. 5A-6A.